Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL1661720 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29723505 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29367714 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9879420 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9878595 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9879191 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29521813 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL3467 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL3468 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9647802 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| US-20250127191-A1 | ANTI-INFLAMMATORY FEED FORMULATION AND USES THEREOF | NAT-PHEN NUTRITION (CA) | 2025-04-24 | — | — | US | claimed |
| US-20250099590-A1 | HIGH DENSITY ULTRASOUND COUPLING GEL AND METHODS OF USE THEREOF | ZETROZ SYSTEMS LLC (US) | 2025-03-27 | — | — | US | claimed |
| WO-2025062440-A1 | TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF | PULSE PHARMACEUTICALS PVT. LTD (IN) | 2025-03-27 | — | — | WO | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119403790-A | Process for preparing hydroxyphenyl-1, 3, 5-triazine compounds | 巴斯夫欧洲公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| EP-4465825-A1 | ANTI-INFLAMMATORY FEED FORMULATION AND USES THEREOF | Nat-Phen Nutrition (CA) | 2024-11-27 | — | — | EP | claimed |
| US-4338311-A | Hydrophilic choline salicylate formulation | RIKER LABORATORIES, INC. (US) | 1982-07-06 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4287174-A | CONTAINING A QUATERNARY AMMONIUM CARBOXY ZWITTERIONIC COMPOUND AND AN ANTACID | THE PROCTOR & GAMBLE COMPANY (US) | 1981-09-01 | — | — | US | claimed |
| US-4275059-A | IN COMBINATION WITH A DIPHOSPHONATE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1981-06-23 | — | — | US | claimed |
| EP-0004686-A2 | Anti-ulcer composition | THE PROCTER & GAMBLE COMPANY (US) | 1979-10-17 | — | — | EP | claimed |
| US-4147776-A | COORDINATION COMPLEX WITH AN ALKALI METAL SULFITE | MUNDIPHARMA, AG (CH) | 1979-04-03 | — | — | US | claimed |
| US-4098813-A | PREPARATION OF ALKALI METAL CHOLINE SALICYLATE SALT COMPLEXES | MUNDIPHARMA AG (CH) | 1978-07-04 | — | — | US | claimed |
| US-4067974-A | Stabilized solid form choline salicylate compositions | THE PURDUE FREDERICK COMPANY (US) | 1978-01-10 | — | — | US | claimed |
| US-4036228-A | Osmotic dispenser with gas generating means | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-3947491-A | INHIBIT COLOR FORMATION | THE PURDUE FREDERICK COMPANY (US) | 1976-03-30 | — | — | US | claimed |